See more : Anthemis Digital Acquisitions I Corp (ADALU) Income Statement Analysis – Financial Results
Complete financial analysis of PainReform Ltd. (PRFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PainReform Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Northern Star Investment Corp. III (NSTC-UN) Income Statement Analysis – Financial Results
- SusGlobal Energy Corp. (SNRG) Income Statement Analysis – Financial Results
- Affiliated Managers Group, Inc. (AMG) Income Statement Analysis – Financial Results
- NJ Holdings Inc. (9421.T) Income Statement Analysis – Financial Results
- PT Hensel Davest Indonesia Tbk (HDIT.JK) Income Statement Analysis – Financial Results
PainReform Ltd. (PRFX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.painreform.com
About PainReform Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 15.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 |
| Gross Profit | -15.00K | 71.00K | -7.00K | 0.00 | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 82.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.04M | 4.42M | 2.86M | 354.00K | 136.00K | 223.00K | 504.00K |
| General & Administrative | 3.48M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Selling & Marketing | 66.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.55M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Cost & Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Interest Income | 406.00K | 160.00K | 0.00 | 1.05K | 588.00 | 0.00 | 245.00K |
| Interest Expense | 384.00K | 61.00K | 10.00K | 987.00K | 541.00K | 324.00K | 0.00 |
| Depreciation & Amortization | 15.00K | 15.00K | 7.00K | 1.00K | 1.00K | 500.00K | 880.00K |
| EBITDA | -9.57M | -8.85M | -7.20M | -1.67M | -688.00K | 0.00 | -1.21M |
| EBITDA Ratio | 0.00% | -10,124.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.58M | -8.87M | -7.21M | -1.67M | -689.00K | -500.00K | -880.00K |
| Operating Income Ratio | 0.00% | -10,312.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 248.00K | 86.00K | -32.00K | -2.16M | -590.00K | -328.00K | -242.00K |
| Income Before Tax | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828.00K | -1.12M |
| Income Before Tax Ratio | 0.00% | -10,212.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.00K | 9.00K | 6.00K | 220.00K | 541.00K | 4.00K | -242.00K |
| Net Income | -9.34M | -8.79M | -7.25M | -4.05M | -1.82M | -828.00K | -2.09M |
| Net Income Ratio | 0.00% | -10,223.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -42.86 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.67 |
| EPS Diluted | -42.83 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.25 |
| Weighted Avg Shares Out | 218.00K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.00K |
| Weighted Avg Shares Out (Dil) | 218.15K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.66K |
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from...
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will...
PainReform Provides Business Update for the Second Quarter of 2023
Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fourth quarter of 2023 Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fourth quarter of 2023
Why Is PainReform (PRFX) Stock Up 38% Today?
PainReform (NASDAQ: PRFX ) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements. According to the company's press release, it was sent notice of it regaining compliance on July 18.
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
TEL AVIV, Israel, July 19, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received notice from Nasdaq on July...
PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
In the world of biotech stocks, one company that's generating big buzz today is PainReform (NASDAQ: PRFX ). The Israeli clinical-stage pharmaceutical company has seen its stock price absolutely skyrocket.
Why Is PainReform (PRFX) Stock Down 40% Today?
PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9...
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
TEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for...
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will...
Why Is PainReform (PRFX) Stock Up 48% Today?
PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the company has received a letter from The Nasdaq Stock Market.
Source: https://incomestatements.info
Category: Stock Reports